Cadila Healthcare settles patent litigation with Upsher-Smith Laboratories

13 Jan 2017 Evaluate

Cadila Healthcare, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA), a leading generic pharmaceutical company in the United States, have finalized an agreement with Upsher-Smith Laboratories, to settle all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules. Under the terms of the agreement, Upsher-Smith grants Zydus a license to market Zydus' generic version of Qudexy XR beginning on March 19, 2020, or earlier under certain circumstances.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×